{"result": {"id": "704643fb-3a69-4b5b-a33d-7937522ae24d", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"China Hypertension Prevention and Treatment Community\",\n    \"summary\": \"This community is centered around the prevention and treatment of hypertension in China, involving a network of organizations, guidelines, and pharmaceutical components. Key entities include the Chinese Hypertension Prevention and Treatment Guidelines Revision Committee, various branches of Chinese medical societies focused on hypertension, and pharmaceutical components like Atorvastatin and Amlodipine. The community is structured around the development, revision, and implementation of hypertension guidelines, with significant contributions from national and international organizations.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the widespread prevalence of hypertension in China and the critical role of this community in managing and reducing the disease's burden.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of Chinese Hypertension Prevention and Treatment Guidelines\",\n            \"explanation\": \"The Chinese Hypertension Prevention and Treatment Guidelines serve as the cornerstone of this community, with the 2024 revision being the most current. These guidelines are the result of collaborative efforts among several key organizations, including the Chinese Hypertension Prevention and Treatment Guidelines Revision Committee, the Chinese Geriatrics Society Hypertension Branch, and the China CDC Non-communicable Disease Prevention and Control Center. The guidelines' revision and implementation are critical for addressing hypertension in China, reflecting the latest medical research and public health strategies. [Data: Entities (816, 819, 822); Relationships (630, 636, 642, 632, 634, +more)]\"\n        },\n        {\n            \"summary\": \"Pharmaceutical Components in Hypertension Treatment\",\n            \"explanation\": \"Pharmaceutical components such as Atorvastatin, Amlodipine, and Folic Acid play significant roles in the community's approach to hypertension treatment. These components are often used in combination to enhance treatment efficacy, highlighting the community's focus on comprehensive and multifaceted treatment strategies. The mention of these components underscores the importance of pharmaceutical innovation and combination therapies in managing hypertension and related cardiovascular conditions. [Data: Entities (1260, 1258, 1256); Relationships (1117, 1118, 1119)]\"\n        },\n        {\n            \"summary\": \"Collaboration with International Standards Organizations\",\n            \"explanation\": \"The community's engagement with international standards organizations, such as the American Association for the Advancement of Medical Instruments and the European Society of Hypertension, indicates a commitment to aligning China's hypertension management practices with global standards. This collaboration is crucial for ensuring the quality and efficacy of hypertension diagnosis and treatment tools, such as blood pressure monitors. [Data: Entities (944, 945); Relationships (788, 789)]\"\n        },\n        {\n            \"summary\": \"National Strategic Plan - Healthy China 2030\",\n            \"explanation\": \"The Healthy China 2030 plan sets specific targets for hypertension awareness and control rates, demonstrating the national importance of hypertension management. This plan is a key driver for the community's activities, emphasizing the government's commitment to improving public health outcomes related to hypertension. The plan's targets serve as a benchmark for the community's efforts in hypertension prevention and treatment. [Data: Entities (873); Relationships (695)]\"\n        },\n        {\n            \"summary\": \"Research and Development in Hypertension Management\",\n            \"explanation\": \"The community benefits from significant research and development efforts, including studies on hypertension prevalence and the effectiveness of combination therapies. Research projects, such as the China Stroke Primary Prevention Study, provide valuable insights into hypertension management strategies, further informing the community's guidelines and treatment approaches. [Data: Entities (1425, 4725); Relationships (1394, 4559)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751560525, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 757, "prompt_tokens": 4193, "total_tokens": 4950, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1472}, "prompt_cache_hit_tokens": 1472, "prompt_cache_miss_tokens": 2721}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n873,健康中国2030,\"A national strategic plan in China with specific targets for hypertension management by 2030\"\"\",2\n1260,阿托伐他汀,\"**阿托伐他汀 (Atorvastatin)** is a pharmaceutical component and a statin drug primarily used for lowering cholesterol levels. It is also employed in combination with other medications to treat hypertension and related cardiovascular conditions. As a statin, it works by inhibiting an enzyme involved in cholesterol production, thereby reducing the risk of heart disease and stroke. Its dual application in managing both cholesterol and hypertension highlights its versatility in cardiovascular therapy.\",3\n320,中国,,17\n949,高血压筛查活动,Global initiatives to improve hypertension awareness through blood pressure measurement campaigns,1\n4435,中等强度他汀类药物,,1\n816,中国高血压防治指南修订委员会,\"The **中国高血压防治指南修订委员会** (Chinese Hypertension Prevention and Treatment Guidelines Revision Committee) is the authoritative committee responsible for revising and updating the Chinese hypertension prevention and treatment guidelines. In 2024, the committee undertook the task of revising these guidelines to ensure they reflect the latest medical research, clinical practices, and public health recommendations for hypertension management in China. Its role encompasses reviewing existing guidelines, incorporating new evidence, and issuing updated recommendations to improve hypertension prevention, diagnosis, and treatment nationwide.\",8\n823,中国高血压防治指南,\"Guidelines for hypertension prevention and treatment in China, first published in 1999 and updated in 2005, 2010, 2018, and 2024\"\"\",9\n819,中国老年医学学会高血压分会,\"The **中国老年医学学会高血压分会** (Chinese Geriatrics Society Hypertension Branch) is a specialized division of the Chinese Geriatrics Society dedicated to the study and management of hypertension. It plays a key role in developing and promoting hypertension management guidelines, contributing to advancements in geriatric healthcare. The branch focuses on addressing hypertension-related issues within the aging population, aligning with the broader objectives of the Chinese Geriatrics Society.\",3\n822,中国疾病预防控制中心慢性非传染性疾病预防控制中心,\"The **中国疾病预防控制中心慢性非传染性疾病预防控制中心** (China CDC Non-communicable Disease Prevention and Control Center) is a division under the Chinese Center for Disease Control and Prevention (China CDC) dedicated to the prevention and control of chronic non-communicable diseases (NCDs). It focuses on addressing long-term health conditions such as cardiovascular diseases, diabetes, cancer, and respiratory diseases through research, policy development, and public health interventions. The center plays a key role in monitoring NCD trends, implementing prevention strategies, and promoting health education to reduce the burden of chronic diseases in China.\",3\n817,高血压联盟(中国),\"Chinese organization focused on hypertension prevention and treatment\"\"\",2\n818,中国医疗保健国际交流促进会高血压病学分会,\"Branch of the China International Exchange and Promotive Association for Medical and Health Care focused on hypertension\"\"\",2\n820,中国老年保健协会高血压分会,\"Branch of the China Elderly Health Association focused on hypertension\"\"\",2\n821,中国卒中学会,\"Chinese organization focused on stroke prevention and treatment\"\"\",2\n824,2018年版中国高血压防治指南,\"Previous version of the Chinese hypertension prevention and treatment guidelines published in 2018\"\"\",2\n825,2024年修订版中国高血压防治指南,\"Updated version of the Chinese hypertension prevention and treatment guidelines published in 2024\"\"\",2\n832,高血压患病率,,2\n829,高血压三率,\"The event of tracking awareness, treatment, and control rates of hypertension in China, currently at 51.6%, 45.8%, and 16.8% respectively\"\"\",2\n830,高血压危险因素,\"The event of identifying key risk factors for hypertension in China, including high sodium diet, obesity, smoking, and alcohol consumption\"\"\",2\n831,高血压防控计划,\"The event of implementing government and professional initiatives to improve hypertension prevention and control in China\"\"\",2\n828,高血压防治指南,The event of updating and publishing the hypertension prevention and treatment guidelines in 2024,1\n827,我国,\"Refers to China, where the hypertension prevalence and control rates are discussed\",4\n944,美国医疗器械促进协会,\"An organization that sets standards for medical devices, including blood pressure monitors\",3\n945,欧洲高血压学会,An organization involved in setting standards for hypertension diagnosis and treatment,2\n946,国际标准组织,\"An international body that sets various standards, including those for medical devices\",2\n1255,依那普利,A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions,2\n1256,叶酸,A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions,3\n1258,氨氯地平,氨氯地平（Amlodipine）是一种钙通道阻滞剂类药物，主要用于治疗高血压和心绞痛。作为医药成分，它常与其他药物联合使用以增强对高血压及相关心血管疾病的疗效。其作用机制是通过阻断钙离子进入血管平滑肌和心肌细胞，从而扩张血管、降低血压，并减少心脏负荷。该药物在临床中兼具单方制剂和复方制剂的应用形式，两种描述分别强调了其药理分类（钙通道阻滞剂）和实际治疗用途（联合用药），本质上并无矛盾，而是从不同角度阐述了同一药物的特性与功能。,2\n1425,中国脑卒中一级预防研究,中国脑卒中一级预防研究显示控制血压的同时补充叶酸可减少脑卒中发生的风险,2\n2117,吴静,\"Co-author of a study on hypertension prevalence in Chinese adults and researcher at China CDC Non-communicable Disease Prevention and Control Center\nA person associated with China CDC Non-communicable Disease Prevention and Control Center\",2\n2146,张梅,,2\n3477,国家老年疾病临床医学研究中心中国老年心血管病防治联盟,\"National Clinical Research Center for Geriatric Diseases, China Elderly Cardiovascular Disease Prevention and Treatment Alliance\"\"\",1\n4724,中华人民共和国科学技术部,\"The Ministry of Science and Technology of China, which funded the research project mentioned in the consensus\",2\n4725,主动健康和老龄化科技应对,A national key research and development project funded by the Ministry of Science and Technology to address health and aging issues,2\n2141,张笑,Co-author of a study on hypertension prevalence in Chinese adults,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n695,健康中国2030,高血压,The plan sets specific targets for hypertension awareness and control rates by 2030,42\n4280,阿托伐他汀,中国,The text mentions that high-dose atorvastatin (80mg) has limited usage experience in the Chinese population,20\n793,高血压筛查活动,中国,Screening activities include measurements conducted in China,18\n4283,中国,中等强度他汀类药物,The text recommends medium-intensity statins for Chinese population due to poor tolerance of high doses,18\n630,中国高血压防治指南修订委员会,中国高血压防治指南,The committee revised the 2024 edition of the guidelines,17\n636,中国老年医学学会高血压分会,中国高血压防治指南,The organization contributed to the guidelines,12\n642,中国疾病预防控制中心慢性非传染性疾病预防控制中心,中国高血压防治指南,The organization contributed to the guidelines,12\n632,高血压联盟(中国),中国高血压防治指南,The organization contributed to the guidelines,11\n634,中国医疗保健国际交流促进会高血压病学分会,中国高血压防治指南,The organization contributed to the guidelines,11\n638,中国老年保健协会高血压分会,中国高血压防治指南,The organization contributed to the guidelines,11\n640,中国卒中学会,中国高血压防治指南,The organization contributed to the guidelines,11\n644,中国高血压防治指南,2018年版中国高血压防治指南,The 2018 version is a previous edition of the guidelines,11\n645,中国高血压防治指南,2024年修订版中国高血压防治指南,The 2024 version is the current updated edition of the guidelines,11\n649,中国高血压防治指南修订委员会,高血压患病率,The committee references hypertension prevalence data in its guidelines,10\n650,中国高血压防治指南修订委员会,高血压三率,The committee references awareness/treatment/control rates in its guidelines,10\n651,中国高血压防治指南修订委员会,高血压危险因素,The committee identifies risk factors in its guidelines,10\n652,中国高血压防治指南修订委员会,高血压防控计划,The committee contributes to national hypertension prevention initiatives,10\n647,中国高血压防治指南修订委员会,高血压防治指南,The committee is responsible for revising and updating the hypertension prevention and treatment guidelines,9\n653,我国,高血压患病率,Hypertension prevalence rates are measured and reported for China,6\n788,美国医疗器械促进协会,欧洲高血压学会,Both organizations collaborate on setting standards for blood pressure measurement devices,5\n789,美国医疗器械促进协会,国际标准组织,Both organizations are involved in standardizing medical device measurements,5\n1117,依那普利,叶酸,Combined in a single medication for treating hypertension,5\n1118,叶酸,氨氯地平,Combined in a single medication for treating hypertension,5\n1119,氨氯地平,阿托伐他汀,Combined in a single medication for treating hypertension and related conditions,5\n1394,中国脑卒中一级预防研究,叶酸,叶酸在中国脑卒中一级预防研究中被证明可减少脑卒中风险,5\n2414,吴静,中国疾病预防控制中心慢性非传染性疾病预防控制中心,\"吴静 is associated with China CDC Non-communicable Disease Prevention and Control Center\nResearcher affiliated with this organization\",5\n646,2018年版中国高血压防治指南,2024年修订版中国高血压防治指南,The 2024 version is an update of the 2018 guidelines,4\n791,欧洲高血压学会,国际标准组织,Both organizations contribute to international standards for hypertension-related devices,4\n2415,吴静,张梅,Co-authors of a hypertension prevalence study,4\n3537,中国老年医学学会高血压分会,国家老年疾病临床医学研究中心中国老年心血管病防治联盟,Collaborated on Chinese elderly hypertension management guidelines,4\n4559,中华人民共和国科学技术部,主动健康和老龄化科技应对,\"The Ministry of Science and Technology funded the \"\"Active Health and Aging Technology Response\"\" project\",4\n2430,张笑,张梅,Co-authors of a hypertension prevalence study,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_1a7d6e9b3ecb316adb3594d7a0ddc293a665982b4e92f3922a26b702f9ee5ce7_v2"}